Therapeutics: c-jun N-terminal kinase (JNK); MAP kinase 1 (MAPK1; ERK-2); MAP kinase 3 (MAPK3; ERK-1)

INDICATION: CardiovascularIn vitro and rodent studies suggest ophiopogonin D could help prevent doxorubicin-induced cardiotoxicity. In rat heart-derived embryonic myocytes, pretreatment with Ophiopogonin japonicas-derived ophiopogonin D protected against doxorubicin-induced reactive oxygen species generation and autophagic cell death through inhibition of ERK-1/ERK-2 and JNK activation. In mice, ophiopogonin D treatment decreased doxorubicin-induced autophagy and prevented cardiac contractile dysfunction compared with doxorubicin treatment alone. Next steps could include testing the protective effects of ophiopogonin D in additional models of doxorubicin cardiotoxicity.

TARGET/MARKER/PATHWAY: c-jun N-terminal kinase (JNK); MAP kinase 1 (MAPK1; ERK-2); MAP kinase 3 (MAPK3; ERK-1)...